<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="6036" end="6042" sStart="6016" offset="20" sid="r11.strong.j.0363" wn="2" wnkey="strong%5:00:00:intense:00" text="CV-1 cells showed a strong response to R1881 compared to vehicle-treated cells with both androgen-responsive reporters used (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="5157" end="5167" sStart="null" offset="83" sid="r10.particular.j.0533" wn="2147483647" wnkey="null" text="These results can add more light to the mechanism by which SHRs, and AR in particular, regulate gene expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="19945" end="19955" sStart="null" offset="102" sid="r10.particular.j.0253" wn="2147483647" wnkey="null" text="These results can help to elucidate the mechanism by which SHRs in general, and AR in particular, regulate gene expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="11143" end="11149" sStart="null" offset="177" sid="r9.level.n.0681" wn="1" wnkey="level%1:07:00::" text="With ARE-TATA-luciferase reporter, luciferase activity was dependent on the presence of AR and androgen, without any effect of Stat3C on the basal levels of transcription (Fig 4, bottom left)." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="18415" end="18421" sStart="null" offset="82" sid="r9.level.n.0337" wn="1" wnkey="level%1:07:00::" text="Another possible mechanism by which a prostate cancer circumvents the low levels of androgens resulting from androgen ablation therapy is by increasing the sensitivity of AR to very low levels of androgens [ 42 ] . Stat3 increased the sensitivity of AR to a dose of androgen that showed no activity in the absence of Stat3, in the absence of a mutated AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="19869" end="19873" sStart="null" offset="26" sid="r10.help.v.0513" wn="3" wnkey="help%2:42:00::" text="These results can help to elucidate the mechanism by which SHRs in general, and AR in particular, regulate gene expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="14132" end="14138" sStart="null" offset="113" sid="r8.family.n.0084" wn="6" wnkey="family%1:14:03::" text="The role of the coactivators could be just as bridging factors, although some of the members of the p160 family and CBP/p300 present histone acetyltransferase activity [ 34 35 ] . Stat3 is a member of the JAK/STAT signaling pathway, which is a transcription factor itself that after activation binds to specific sequences in DNA to regulate expression of genes related to proliferation, differentiation and cell survival." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="14132" end="14138" sStart="null" offset="113" sid="r8.family.n.0084" wn="3" wnkey="family%1:14:04::" text="The role of the coactivators could be just as bridging factors, although some of the members of the p160 family and CBP/p300 present histone acetyltransferase activity [ 34 35 ] . Stat3 is a member of the JAK/STAT signaling pathway, which is a transcription factor itself that after activation binds to specific sequences in DNA to regulate expression of genes related to proliferation, differentiation and cell survival." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="14132" end="14138" sStart="null" offset="113" sid="r8.family.n.0084" wn="4" wnkey="family%1:14:01::" text="The role of the coactivators could be just as bridging factors, although some of the members of the p160 family and CBP/p300 present histone acetyltransferase activity [ 34 35 ] . Stat3 is a member of the JAK/STAT signaling pathway, which is a transcription factor itself that after activation binds to specific sequences in DNA to regulate expression of genes related to proliferation, differentiation and cell survival." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="1550" end="1558" sStart="null" offset="66" sid="r8.family.n.0787" wn="3" wnkey="family%1:14:04::" text="The recent findings that members of the several different families of coactivators possess intrinsic histone acetyltransferase activity suggests that activated SHRs, and nuclear receptors in general, may also recruit these cofactors to remodel chromatin structure for better accessibility of the transcriptional machinery to DNA [ 5 6 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="2808" end="2814" sStart="null" offset="397" sid="r8.family.n.0723" wn="3" wnkey="family%1:14:04::" text="Similarly to nuclear receptors and to other transcription factors, STAT proteins can interact with coactivators to modulate their transcriptional activity [ 9 10 11 12 ] . Other reports have shown direct interactions between several members of the JAK/STAT signaling pathway with SHRs [ 13 14 15 16 ] . Stat3 is one of the seven members of the STAT family of proteins that has been shown to modulate the expression of several genes related to control cell cycle, proliferation and apoptosis, such as Cyclin D1, c-myc, and Bcl-xL, respectively [ 17 ] . Accordingly, alterations in the activity of STAT3 have been associated with cell transformation and cancer progression [ 18 19 20 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="14132" end="14138" sStart="null" offset="113" sid="r8.family.n.0084" wn="3" wnkey="family%1:14:04::" text="The role of the coactivators could be just as bridging factors, although some of the members of the p160 family and CBP/p300 present histone acetyltransferase activity [ 34 35 ] . Stat3 is a member of the JAK/STAT signaling pathway, which is a transcription factor itself that after activation binds to specific sequences in DNA to regulate expression of genes related to proliferation, differentiation and cell survival." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="9994" end="10003" sStart="null" offset="139" sid="r8.1.different.j.0058" wn="1" wnkey="different%3:00:00::" text="Altered responses of AR include activation by non-androgen ligands or recognition of other hormone responsive elements different from AREs [ 22 23 ] . We studied if active Stat3 could be responsible for this behavior of AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="13178" end="13187" sStart="null" offset="39" sid="r8.1.different.j.0054" wn="1" wnkey="different%3:00:00::" text="Cells were then treated with different doses of androgen." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="9994" end="10003" sStart="null" offset="139" sid="r8.1.different.j.0058" wn="1" wnkey="different%3:00:00::" text="Altered responses of AR include activation by non-androgen ligands or recognition of other hormone responsive elements different from AREs [ 22 23 ] . We studied if active Stat3 could be responsible for this behavior of AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="13178" end="13187" sStart="null" offset="39" sid="r8.1.different.j.0054" wn="1" wnkey="different%3:00:00::" text="Cells were then treated with different doses of androgen." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="9994" end="10003" sStart="null" offset="139" sid="r8.1.different.j.0058" wn="1" wnkey="different%3:00:00::" text="Altered responses of AR include activation by non-androgen ligands or recognition of other hormone responsive elements different from AREs [ 22 23 ] . We studied if active Stat3 could be responsible for this behavior of AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="13178" end="13187" sStart="null" offset="39" sid="r8.1.different.j.0054" wn="1" wnkey="different%3:00:00::" text="Cells were then treated with different doses of androgen." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="9994" end="10003" sStart="null" offset="139" sid="r8.1.different.j.0058" wn="2" wnkey="different%5:00:00:other:00" text="Altered responses of AR include activation by non-androgen ligands or recognition of other hormone responsive elements different from AREs [ 22 23 ] . We studied if active Stat3 could be responsible for this behavior of AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="13178" end="13187" sStart="null" offset="39" sid="r8.1.different.j.0054" wn="1" wnkey="different%3:00:00::" text="Cells were then treated with different doses of androgen." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1478-1336-1-3.anc" start="1195" end="1199" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" text="To &lt;b&gt;date&lt;/b&gt;, numerous coactivator molecules have been isolated and characterized, encompassing several different families [ 3 4 ] . Most of these cofactors are expressed in a wide variety of cell types and can interact with more than one type of nuclear receptor." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="15968" end="15974" sStart="null" offset="214" sid="r10.common.j.0482" wn="2" wnkey="common%3:00:01::" text="Moreover, Stat3 has also been directly associated with several coactivators, such as SRC-1 and CBP/p300 [ 9 12 ] . Recruitment of coactivators to nuclear receptors takes place via a common motif in the coactivators containing a core consensus sequence LXXLL (L, leucine; X, any aminoacid) [ 38 ] . Most of the coactivators contain more than one of these motifs, raising the question regarding specificity of these motifs to specific activating domains in the nuclear receptors." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="8837" end="8848" sStart="null" offset="42" sid="r11.combination.n.0984" wn="7" wnkey="combination%1:04:00::" text="It has been reported that coactivators in combination can enhance transcriptional activity of SHRs compared to when they are delivered to cells individually [ 29 30 ] . Recently, Giraud et al [ 12 ] reported a direct interaction of Stat3 with SRC-1 and CBP/p300." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="269" end="276" sStart="null" offset="7" sid="r11.absence.n.0880" wn="1" wnkey="absence%1:26:00::" text="In the absence of ligand such as androgen, glucocorticoid, progestin, and mineralocorticoid, the SHR maintains a cytosolic inactive state by association with heat shock proteins and/or other proteins such as corepressors." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="10893" end="10900" sStart="null" offset="266" sid="r11.absence.n.0574" wn="1" wnkey="absence%1:26:00::" text="To test whether Stat3 could alter the specificity of AR to other HREs, CV-1 cells were cotransfected with reporter plasmids responsive to androgen (ARE-TATA-luciferase) or to estrogen (ERE-TATA-luciferase), in the presence or absence of AR and constitutively active Stat3C (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="12227" end="12234" sStart="null" offset="136" sid="r11.absence.n.0295" wn="1" wnkey="absence%1:26:00::" text="CV-1 cells cotransfected with an androgen responsive reporter plasmid (ARE-TATA-luciferase), AR, in the presence or absence of constitutively active Stat3C, were treated with androgen and flutamide (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="18679" end="18686" sStart="null" offset="346" sid="r11.absence.n.0157" wn="1" wnkey="absence%1:26:00::" text="Another possible mechanism by which a prostate cancer circumvents the low levels of androgens resulting from androgen ablation therapy is by increasing the sensitivity of AR to very low levels of androgens [ 42 ] . Stat3 increased the sensitivity of AR to a dose of androgen that showed no activity in the absence of Stat3, in the absence of a mutated AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="10257" end="10264" sStart="null" offset="138" sid="r11.absence.n.0851" wn="1" wnkey="absence%1:26:00::" text="CV-1 cells were cotransfected with a reporter plasmid responsive to androgen (ARE-TATA-luciferase) in the presence or absence of AR and constitutively active Stat3C (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="12456" end="12463" sStart="null" offset="127" sid="r11.absence.n.0701" wn="1" wnkey="absence%1:26:00::" text="As expected, flutamide blocked substantially the induction of ARE-TATA-luciferase activity by R1881 in the absence of active Stat3C." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="13098" end="13105" sStart="null" offset="377" sid="r11.absence.n.0041" wn="1" wnkey="absence%1:26:00::" text="Other mechanism by which AR could show an altered response results from an increase in its sensitivity to very low levels of androgen [ 22 23 ] . We tested the role of active Stat3 in this possibility cotransfecting CV-1 cells with an androgen responsive reporter (ARE-TATA-luciferase), AR, in the presence or in the absence of constitutively active Stat3C." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="18704" end="18711" sStart="null" offset="371" sid="r11.absence.n.0129" wn="1" wnkey="absence%1:26:00::" text="Another possible mechanism by which a prostate cancer circumvents the low levels of androgens resulting from androgen ablation therapy is by increasing the sensitivity of AR to very low levels of androgens [ 42 ] . Stat3 increased the sensitivity of AR to a dose of androgen that showed no activity in the absence of Stat3, in the absence of a mutated AR." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-3.anc" start="13098" end="13105" sStart="null" offset="377" sid="r11.absence.n.0041" wn="1" wnkey="absence%1:26:00::" text="Other mechanism by which AR could show an altered response results from an increase in its sensitivity to very low levels of androgen [ 22 23 ] . We tested the role of active Stat3 in this possibility cotransfecting CV-1 cells with an androgen responsive reporter (ARE-TATA-luciferase), AR, in the presence or in the absence of constitutively active Stat3C." />
  </sentences>
</list>